Ark Therapeutics Group Plc - Price Analysis Snapshot

This Report features up to a ten-year record of the equity Price history for Ark Therapeutics Group Plc. Tabular results include the High, Low and Closing price for the quarter. There is also a calculation of percentage change in price for both Quarterly and Annual periods. Price values are adjusted for stock splits and dividends.

Ark Therapeutics Group Plc. The Group's principal activity is discovering, developing and commercialising products in areas of specialist medicine with particular focus on vascular disease and cancer. Its pharmaceutical business focuses on gene-based medicine that harnesses healthy brain cells to destroy cancer cells that attempt to proliferate. It is used for the treatment of patients with operable high-grade glioma, where the average survival period for patients, once diagnosed, is about eight months. It also has products designed to prevent the blocking of veins after vascular surgery. Product brands are Cerepro, Vitor and Trinam. In addition, the Group also has wound care portfolio centered on the prevention and treatment of foot, lower-leg and infected wounds. Its product brands include Kerrabot, Kerraped, Neuropad and Flaminal. The Group operates in the United Kingdom and Finland.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report